Insider Selling: FibroGen, Inc (FGEN) Insider Sells 15,000 Shares of Stock

FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $60.00, for a total transaction of $900,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

K Peony Yu also recently made the following trade(s):

  • On Monday, October 2nd, K Peony Yu sold 40,000 shares of FibroGen stock. The stock was sold at an average price of $54.63, for a total transaction of $2,185,200.00.
  • On Thursday, September 14th, K Peony Yu sold 2,851 shares of FibroGen stock. The stock was sold at an average price of $51.00, for a total transaction of $145,401.00.
  • On Monday, August 21st, K Peony Yu sold 7,500 shares of FibroGen stock. The stock was sold at an average price of $41.03, for a total transaction of $307,725.00.
  • On Tuesday, August 8th, K Peony Yu sold 37,500 shares of FibroGen stock. The stock was sold at an average price of $50.58, for a total transaction of $1,896,750.00.
  • On Tuesday, August 1st, K Peony Yu sold 10,000 shares of FibroGen stock. The stock was sold at an average price of $33.48, for a total transaction of $334,800.00.
  • On Monday, July 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $32.98, for a total transaction of $164,900.00.

FibroGen, Inc (NASDAQ:FGEN) opened at 55.30 on Wednesday. The company has a 50 day moving average price of $52.02 and a 200 day moving average price of $36.39. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15. The firm’s market capitalization is $3.94 billion.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The business had revenue of $29.00 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Analysts anticipate that FibroGen, Inc will post ($1.81) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://baseballnewssource.com/markets/fibrogen-inc-fgen-insider-sells-900000-00-in-stock/1700549.html.

FGEN has been the topic of a number of recent analyst reports. Leerink Swann reissued an “outperform” rating and issued a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup Inc. lifted their price target on FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a report on Tuesday, August 8th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $38.00 price objective (up from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $65.67.

A number of hedge funds have recently modified their holdings of the business. SG Americas Securities LLC increased its holdings in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 412 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its holdings in FibroGen by 1.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 474 shares in the last quarter. Principal Financial Group Inc. increased its holdings in FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after purchasing an additional 504 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 696 shares in the last quarter. Finally, Tudor Investment Corp ET AL increased its holdings in FibroGen by 7.1% in the second quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after purchasing an additional 799 shares in the last quarter. Institutional investors and hedge funds own 47.49% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.